

## Special Issue

# Immune Checkpoint Inhibitor Therapy 2024

### Message from the Guest Editor

Immunotherapy has provoked a paradigm shift in the treatment of cancer. Since 2013, we have known that immunotherapy is fundamental to the treatment of tumors such as melanoma, non-small cell lung carcinoma, head and neck carcinoma, and bladder carcinoma. Different immune checkpoints such as PD(L)1 or CTLA-4 inhibitors have become the first agents to obtain FDA and EMA approval for the treatment of various carcinomas. Despite all efforts, there remain some patients who are primarily resistant or who become resistant after treatment. T cell exhaustion, T regs upregulation, or MDSC activity have been proposed as the mechanisms implicated in resistance to immunotherapy agents. To overcome this lack of response to immunotherapy agents, different approaches, such as combinations with chemotherapy, radiotherapy, or targeted therapy, are under investigation. At this point, it is not only tumor mutations that are relevant to choosing the suitable treatment, but a deeper knowledge of the host immune system is also required.

---

### Guest Editor

Dr. Eduardo Castañón Álvarez

Department of Oncology, Clínica Universidad de Navarra, 31008 Pamplona, Spain

---

### Deadline for manuscript submissions

closed (15 January 2024)



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.3  
CiteScore 6.1  
Indexed in PubMed



[mdpi.com/si/181981](https://mdpi.com/si/181981)

*Pharmaceuticals*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.3  
CiteScore 6.1  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Pharmaceutical Science)